| Anticancer Fund

Launch of a Call for Research Proposal

Tue, 12/17/2019 - 12:00

Low-dose azacytidine, pioglitazone and retinoic acid in ≥ 60 years patients with acute myeloid leukaemia refractory to chemotherapy (AML-ViVA)

Presented on the 61st ASH Annual Meeting & Exposition

Mon, 12/09/2019 - 12:00

Intraoperative ketorolac in High-Risk Breast Cancer Patients. A Prospective, Randomized, Placebo-Controlled Clinical Trial.

Patrice Forget, Gauthier Bouche, Francois P. Duhoux, Pierre G. Coulie,Jan Decloedt, Alain Dekleermaker, Jean-Edouard Guillaume, Marc Ledent, Jean- Pascal Machiels, Véronique Mustin, Walter Swinnen, Aline van Maanen, Lionel Vander Essen, Jean-Christophe Verougstraete, Marc De Kock, Martine Berliere (2019) - Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. PLoS ONE 14(12): e0225748. https://doi.org/10.1371/journal.pone.0225748

Thu, 12/05/2019 - 12:00

More than 300 existing drugs have anticancer effects

Thu, 11/14/2019 - 12:00

Cancer patients should be aware of scientific misinformation

Tue, 11/05/2019 - 12:00

Journal retractions in oncology: a bibliometric study

Pan Pantziarka, Lydie Meheus - Journal retractions in oncology: a bibliometric study. Future Medicine, 15 (31), DOI: 10.2217/fon-2019-0233

Tue, 11/05/2019 - 12:00

Phase I Study of Fluvastatin/Celecoxib Combination in Children with Relapsing or Refractory Low or High Grade Glioma - First Results

Presented at SIOP 2019

Sat, 10/26/2019 - 12:00

Lung Cancer Survival Gains: Contributions of Academia and Industry

Bishal Gyawali, Gauthier Bouche, Pan Pantziarka, Aaron S. Kesselheim, Ameet Sarpatwari (2019) - Lung Cancer Survival Gains: Contributions of Academia and Industry. The Journal of Law, Medicine & Ethics, 47 (2019): 465-467. DOI: 10.1177/1073110519876182

Mon, 09/30/2019 - 12:00